5 Questions Novo Nordisk Must Answer to Drive Its Stock Higher
Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...
Novo Nordisk Expands AI Partnership With Valo Health for Development of Obesity Drugs
Novo and Valo originally partnered in September 2023 in an agreement to develop up to 11 drugs. With the expanded agreement, ...
Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pact
At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...
Novo, Eli Lilly to dominate global pharma sales in 2025: report
Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...
DPA International on MSN2d
Novo Nordisk expands drug collaboration with Valo Health
Denmark's Novo Nordisk on Wednesday announced an expansion of its collaboration with Valo Health to discover and develop ...
Goldman Sachs Remains a Buy on Novo Nordisk (0QIU)
Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK875.00.
Better Buy: Novo Nordisk vs. AstraZeneca
Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals
Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...
Seattle genomics startup Variant Bio signs deal with Novo Nordisk worth up to $50M
Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...
Does Novo Nordisk A/S (NVO) Have an Attractive Valuation?
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth ...
Alzheimer’s drugs eyed as next big obesity-like opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...